SIRION Biotech Plans Opening of a New Office in the Boston Area

BOSTON & MUNICH--(BUSINESS WIRE)--SIRION Biotech, a leading viral vector platform company known for creating high quality viral vector solutions for industry and academic partners, today announced its commitment to open a new office in the vicinity of Boston. The announcement was made during the 2015 BIO International Convention taking place this week in Philadelphia, Pennsylvania.

"Our suite of proprietary products and services enables us to provide the highest quality tools for downstream applications in gene therapy and vaccine development."

SIRION is working with the Massachusetts Life Sciences Center (MLSC) to locate lab and office space for the Company, which will prove to be a pivotal step in SIRION's U.S. expansion. SIRION's office in the Boston area will allow direct access to Massachusetts' vibrant life science community, which includes an increasing number of biotechnology companies and academic researchers working to develop gene therapies and vaccines for a range of diseases.

"We appreciate the assistance from Massachusetts Life Sciences Center in helping us begin building our U.S. operations in the Boston area, during such an exciting time in our industry," said Dieter Lingelbach, Chief Operating Officer of SIRION Biotech. "We are a growing company, planning to build on the success we've had in Europe, Israel and Japan, as we collaborate with many companies pioneering gene therapies."

"We are pleased to welcome SIRION to Massachusetts, where the gene therapy space continues to receive significant attention from stakeholders in the life sciences due to its potential to cure a variety of diseases," said Angus McQuilken, MLSC Vice President for Communications & Marketing. "SIRION will be a great addition to this growing part of the Massachusetts life sciences ecosystem."

"We're so excited to welcome SIRION to the Massachusetts super cluster and know it is going to hit the ground running as a valuable partner to the companies and organizations here," said Robert K. Coughlin, President and CEO at MassBio.

SIRION provides customizable versions of all three major viral vector types, adenovirus (AV), adeno-associated virus (AAV) and lentivirus (LV), and offers expertise in transduction of various cell lines, an essential piece of all genetic applications. SIRION's high quality products and well established processes coupled with its commitment to addressing each client's unique needs, has established the Company as a leader in viral vector solutions. SIRION's expertise in custom viral vector solutions and process development makes SIRION an ideal collaborative partner.

"Producing products of the highest quality, purity and yield are of paramount importance and is also one of the biggest challenges," said Dr. Christian Thirion, Founder and CTO. "Our suite of proprietary products and services enables us to provide the highest quality tools for downstream applications in gene therapy and vaccine development."

About SIRION Biotech GmbH

Founded in 2005, SIRION Biotech is a global leader in developing research and commercial grade viral vector solutions for industry and academic partners who are developing gene therapies and vaccines. With the broadest vector portfolio that produces products with the highest yield, purity and quality, SIRION provides reliable, custom-engineered viral vector solutions for leading pharmaceutical companies, development-stage biotechnology companies and academic scientists and researchers. SIRION Biotech strives to be the world's leading viral vector partner, meeting a critical need in the process of bringing groundbreaking gene therapies and novel vaccines to patients across a broad spectrum of indications. In addition to new facilities in Massachusetts, U.S., SIRION is headquartered in Germany with a strong presence in Israel and Japan.

About the Massachusetts Life Sciences Center

The Massachusetts Life Sciences Center (MLSC) is an investment agency that supports life sciences innovation, research, development and commercialization. The MLSC is charged with implementing a 10-year, $1-billion, state-funded investment initiative. These investments create jobs and support advances that improve health and well-being. The MLSC offers the nation's most comprehensive set of incentives and collaborative programs targeted to the life sciences ecosystem. These programs propel the growth that has made Massachusetts the global leader in life sciences. The MLSC creates new models for collaboration and partners with organizations, both public and private, around the world to promote innovation in the life sciences. For more information, visit

This announcement is not intended to be a commercial endorsement by the MLSC of any products or services provided or developed by the entities referenced in this release.

Corporate Contacts:
SIRION Biotech
Dieter Lingelbach, +49 (176) 633 89041
Chief Operating Officer
[email protected]
Carl Christel, 857-284-1844
Senior Manager, Sales & Marketing
[email protected]
Media & Investor Contact:
David Connolly, 617-374-8800 ext. 108
[email protected]
Massachusetts Life Sciences Center Contact:
Angus G. McQuilken, 617-921-7749
[email protected]